NCT05364229Active, not recruiting
MR-guided Tumour Boost
MR-guided Tumour Boost With Stereotactic Body Radiotherapy in Prostate Cancer
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 3 May 2022
- Start date
- 6 Feb 2023
- Primary completion date
- Jun 2030
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Prostate cancer
- NCT number
- NCT05364229
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 6 Feb 2023 to the primary completion date, Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy to pelvis
Other illness
- Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
- Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
Other
- Radiological evidence of regional or distant metastases at the discretion of the treating physician.
- Ataxia Telangectasia and SLE
- Severe claustrophobia
Who the study is looking for
- Histologically-proven localized prostate cancer.
- Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
- Low-risk: cT1-T2a, PSA \<10, and Gleason score 6
- Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
- High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7
- Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume
- Planned for EBRT (+/- ADT)
- ECOG 0 or 1
- 18 years of age or older
- Ability to provide written informed consent to participate in the study
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network, Princess Margaret Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.